Amanda J. Littlewood-Evans

Supplementary Data from Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo

Susana N. Banerjee, Roger A’Hern, Simone I. DETRE, Amanda J. Littlewood-Evans et autres

Supplementary Figure S1.

Supplementary Figures S1-S4 from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Heidi A. Lane, Jeanette Marjorie Wood, Paul M.J. McSheehy, Peter Roland ALLEGRINI et autres

Supplementary Figures S1-S4 from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Data from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Heidi A. Lane, Jeanette Marjorie Wood, Paul M.J. McSheehy, Peter Roland ALLEGRINI et autres

Abstract Purpose: Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular endothelial growth factor receptor (VEGFR) inhibitor vatalanib (PTK/ZK). Experimental Design: Antiproliferative activity against various tumor histotypes and downstream effects on the …

Data from Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo

Susana N. Banerjee, Roger A’Hern, Simone I. DETRE, Amanda J. Littlewood-Evans et autres

Abstract Purpose: Targeting vascular endothelial growth factor (VEGF) and estrogen receptor signaling pathways concomitantly may enhance benefit in estrogen receptor–positive breast cancer. We had shown previously that the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 (PTK/ZK) is a competitive aromatase inhibitor in vitro. …

us, gb, ch (code pays fourni par la source)

Data from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Heidi A. Lane, Jeanette Marjorie Wood, Paul M.J. McSheehy, Peter Roland ALLEGRINI et autres

Abstract Purpose: Comparison of the antiangiogenic/vascular properties of the oral mammalian target of rapamycin (mTOR) inhibitor RAD001 (everolimus) and the vascular endothelial growth factor receptor (VEGFR) inhibitor vatalanib (PTK/ZK). Experimental Design: Antiproliferative activity against various tumor histotypes and downstream effects on the …

Data from Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo

Susana N. Banerjee, Roger A’Hern, Simone I. DETRE, Amanda J. Littlewood-Evans et autres

Abstract Purpose: Targeting vascular endothelial growth factor (VEGF) and estrogen receptor signaling pathways concomitantly may enhance benefit in estrogen receptor–positive breast cancer. We had shown previously that the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 (PTK/ZK) is a competitive aromatase inhibitor in vitro. …

Supplementary Figures S1-S4 from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Heidi A. Lane, Jeanette Marjorie Wood, Paul M.J. McSheehy, Peter Roland ALLEGRINI et autres

Supplementary Figures S1-S4 from mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Supplementary Data from Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo

Susana N. Banerjee, Roger A’Hern, Simone I. DETRE, Amanda J. Littlewood-Evans et autres

Supplementary Figure S1.

Data from Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics

Patrizia Sini, Ivana Samaržija, Fabienne Baffert, Amanda J. Littlewood-Evans et autres

Abstract Vascular endothelial growth factor receptors (VEGFR) have important roles in cancer, affecting blood and lymphatic vessel functionality as well as tumor cells themselves. We compared the efficacy of a VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), which targets the three VEGFRs, with …

Supplementary Figures 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Christian Schnell, Frédéric Stauffer, Peter Roland ALLEGRINI, Terence O’Reilly et autres

Supplementary Figures 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Supplementary Figure Legends 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Christian Schnell, Frédéric Stauffer, Peter Roland ALLEGRINI, Terence O’Reilly et autres

Supplementary Figure Legends 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Supplementary Figures 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Christian Schnell, Frédéric Stauffer, Peter Roland ALLEGRINI, Terence O’Reilly et autres

Supplementary Figures 1-3 from Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging